BNP Paribas Asset Management
CSTL icon

BNP Paribas Asset Management’s Castle Biosciences CSTL Stock Holding History

BNP Paribas Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7K Sell
761
-1,078
-59% -$35.3K ﹤0.01% 2058
2025
Q4 		$72K Buy
1,839
+1,378
+299% +$44.4K ﹤0.01% 1559
2025
Q3 		$10K Buy
461
+33
+8% +$670 ﹤0.01% 1625
2025
Q2 		$9K Buy
+428
New +$7.92K ﹤0.01% 1804

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Asset Management's CSTL Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Castle Biosciences (CSTL) stake by 59% in Q1 2026, selling an estimated $35.3K and leaving 761 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2058.

BNP Paribas Asset Management first reported a position in CSTL in Q2 2025 and has held it in 4 quarters since. The position peaked at $72K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • BNP Paribas Asset Management held 761 shares of Castle Biosciences worth $18.7K as of Q1 2026.
  • BNP Paribas Asset Management sold 1,078 Castle Biosciences shares in Q1 2026, an estimated $35.3K.
  • Castle Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2058 holding.
  • BNP Paribas Asset Management first reported a position in Castle Biosciences in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Castle Biosciences position peaked at $72K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.